Dr. Eric Sasso, Vice President of Medical and Scientific Affairs for Crescendo Bioscience, explains how treatment for rheumatoid arthritis (RA) has improved greatly over the past decade. Even though the majority of new RA patients are treated with methotrexate, an effective drug therapy for the condition, over half will still need a second form of therapy to experience better relief from their symptoms.
Understanding the patients disease activity is the key to delivering the right care to each patient. Aside from examining the patients’ joints and asking for verbal feedback, there is a new blood test that will help physicians in their quest to tailor the right therapeutic regimens to each individual person they treat. The Vectra™ DA test will provide a score from 0 to 100 that will give rheumatologists clues about which particular therapies and drugs to prescribe to achieve optimum effectiveness.